English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  DetailsSummary

Released
Journal Article

Hypertriglyceridaemia Secondary to Liver Disease

MPS-Authors
/persons/resource/persons15555

Müller,  P.
Department of Molecular Developmental Biology, MPI for biophysical chemistry, Max Planck Society;

/persons/resource/persons86998

Agostini,  Bruno
Department of Biomedical Optics, Max Planck Institute for Medical Research, Max Planck Society;

/persons/resource/persons95928

Wieland,  Heike
Department of Molecular Neurobiology, Max Planck Institute for Medical Research, Max Planck Society;

/persons/resource/persons205788

Seidel,  D.
Max Planck Institute for Medical Research, Max Planck Society;

External Resource

https://doi.org/10.1111/j.1365-2362.1974.tb02357.x
(Any fulltext)

Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Müller, P., Fellin, R., Lambrecht, J., Agostini, B., Wieland, H., Rost, W., et al. (1974). Hypertriglyceridaemia Secondary to Liver Disease. European Journal of Clinical Investigation, 4(6), 419-428. doi:10.1111/j.1365-2362.1974.tb02357.x.


Cite as: https://hdl.handle.net/11858/00-001M-0000-002D-FABB-D
Abstract
Abstract. Some patients with liver dysfunction show a marked hypertriglyceridaemia, a phenomenon most frequently accompanied by cholestasis. In this report we have identified, isolated and characterized an abnormally large (300–700 Å), triglyceride rich, low density lipoprotein, (d 1.019-1.063 g/ml) designated β-lipoprotein (β2-LP), from the plasma of patients with hypertriglyceridaemia secondary to liver disease. The βa-LP differs significantly in its percent composition and protein moiety from the unique lipoprotein-X (LP-X) specific for cholestasis and also from normal β-lipoproteins, both of which are also present in the patients LDL fraction. Furthermore, some evidence is provided suggesting that the β2-LP is likely to represent an intermediate particle of chylomicron metabolism, which accumulates in this disease due to a markedly diminished hepatic lipase activity.